References - Women's Health Protocol

1.    Lukaski HC.  "Vitamin and mineral status: effects on physical performance."  Nutrition. 2004 Jul-Aug;20(7-8):632-44.

 

2.    Harrison RA, Holt D, Pattison DJ, Elton PJ.  "Are those in need taking dietary supplements? A survey of 21 923 adults."  Br J Nutr. 2004 Apr;91(4):617-23.  

   
3.    Benton, D., “The impact of long-term vitamin supplementation on cognitive functioning,” Psychopharmacology 117 (1995) 298-305.    

4.    Paulionis L, Kane SL, Meckling KA.  "Vitamin status and cognitive function in a long-term care population."  

5.    Bryan J, Osendarp S, Hughes D, Calvaresi E, Baghurst K, van Klinken JW.  "Nutrients for cognitive development in school-aged children." Nutr Rev. 2004 Aug;62(8):295-306.          

       
6.    Suitor CW, Gleason PM.  "Using Dietary Reference Intake-based methods to estimate the prevalence of inadequate nutrient intake among school-aged children." J Am Diet Assoc. 2002 Apr;102(4):530-6.     

7.    Heinrich U, Tronnier H, Stahl W, Bejot M, Maurette JM.  "Antioxidant supplements improve parameters related to skin structure in humans."  Skin Pharmacol Physiol. 2006;19(4):224-31.             

8.    Kang HJ, Ansbacher R, Hammoud MM.   "Use of alternative and complementary medicine in menopause."  Int J Gynaecol Obstet. 2002 Dec;79(3):195-207.                

9.    Somekawa Y, Chiguchi M, Ishibashi T, Wakana K, Aso T.   "Efficacy of ipriflavone in preventing adverse effects of leuprolide."  J Clin Endocrinol Metab. 2001 Jul;86(7):3202-6.                 

10.    Gennari C, Adami S, et al.   "Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass."  Calcif Tissue Int. 1997;61 Suppl 1:S19-22.

11.     Geller SE, Studee L.  "Botanical and dietary supplements for menopausal symptoms: what works, what does not."  J Womens Health (Larchmt). 2005 Sep;14(7):634-49.          

                                   
12.    Wuttke W, Jarry H, et al. "Chaste tree (Vitex agnus-castus)--pharmacology and clinical indications."  Phytomedicine. 2003 May;10(4):348-57.         

13.    Loch EG, Selle H, Boblitz N.  "Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus." J Womens Health Gend Based Med. 2000 Apr;9(3):315-20.     

14.    Berger D, Schaffner W, Schrader E, Meier B, Brattstrom A.  "Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS)."  Arch Gynecol Obstet. 2000 Nov;264(3):150-3.

15.    Schellenberg R.   "Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study."  BMJ. 2001 Jan 20;322(7279):134-7.         

16.    Centers for Disease Control and Prevention (CDC).  "Toddler deaths resulting from ingestion of iron supplements--Los Angeles, 1992-1993."  MMWR Morb Mortal Wkly Rep. 1993 Feb 19;42(6):111-3.

17.    http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/iro_0149.shtml

18.    Dent CE, Davies IJ. "Calcium metabolism in bone disease: effects of treatment with microcrystalline calcium hydroxyapatite compound and dihydrotachysterol."  J R Soc Med. 1980 Nov;73(11):780-5.     

            
19.    Pines A, Raafat H, Lynn AH, Whittington J.  "Clinical trial of microcrystalline hydroxyapatite compound ('Ossopan') in the prevention of osteoporosis due to corticosteroid therapy."  Curr Med Res Opin. 1984;8(10):734-42.       

         
20.    Stellon A, Davies A, Webb A, Williams R.  "Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis." Postgrad Med J. 1985 Sep;61(719):791-6.

 

  21.    Castelo-Branco C, Pons F, Vicente JJ, Sanjuan A, Vanrell JA.  "Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year, prospective trial."  J Reprod Med. 1999 Jul;44(7):601-5.                                            
22.    Epstein O, Kato Y, Dick R, Sherlock S.  "Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis."  Am J Clin Nutr. 1982 Sep;36(3):426-30.          

     
23.    Rüegsegger P, et al., “Comparison of the treatment effect of ossein-hydroxyapatite compound and  calcium carbonate in osteoporotic females,” Osteoporosis Int 5, 1 (1995) 30-4.            

    
24.    Kohn R, “Historical review of microcrystalline hydroxyapatite compound,” in Osteoporosis, A Multi-disciplinary Problem, edited by A. St. J. Dixon,et al. in Royal Society of Medicine International Congress and Symposium Series No. 55 ( 1983) 265-267.    

25.    Di Daniele N, et al.   "Effect of supplementation of calcium and vitamin D on bone mineral density and bone mineral content in peri- and post-menopause women; a double-blind, randomized, controlled trial."  Pharmacol Res. 2004 Dec;50(6):637-41.        

26.    Nielsen FH.  "Studies on the relationship between boron and magnesium which possibly affects the formation and maintenance of bones."  Magnes Trace Elem. 1990;9(2):61-9.         

       
27.    Rude RK, Gruber HE.   "Magnesium deficiency and osteoporosis: animal and human observations."  J Nutr Biochem. 2004 Dec;15(12):710-6.        

28.    Saltman PD, Strause LG.  "The role of trace minerals in osteoporosis."  J Am Coll Nutr. 1993 Aug;12(4):384-9.

29.    Schaafsma A, et al.  "Vitamin D(3) and vitamin K(1) supplementation of Dutch postmenopausal women with normal and low bone mineral densities: effects on serum 25-hydroxyvitamin D and carboxylated osteocalcin."  Eur J Clin Nutr. 2000 Aug;54(8):626-31.

30.    Strause L, Saltman P, Smith KT, Bracker M, Andon MB.  "Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals."  J Nutr. 1994 Jul;124(7):1060-4.         

   
31.    Volpe SL, Taper LJ, Meacham S.  "The relationship between boron and magnesium status and bone mineral density in the human: a review."  Magnes Res. 1993 Sep;6(3):291-6.

32.    http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/cal_0052.shtml

33.    "[No authors listed]  Gamma-linolenic acid (GLA). Monograph. Altern Med Rev. 2004 Mar;9(1):70-8.  "

34.    Kapoor R, Huang YS.  "Gamma linolenic acid: an antiinflammatory omega-6 fatty acid." Curr Pharm Biotechnol. 2006 Dec;7(6):531-4.      

 
35.    Song C, Li X, Leonard BE, Horrobin DF.  "Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats."  J Lipid Res. 2003 Oct;44(10):1984-91.   

 
36.    Barabino S, Rolando M, Camicione P, Ravera G, Zanardi S, Giuffrida S, Calabria G.   "Systemic linoleic and gamma-linolenic acid therapy in dry eye syndrome with an inflammatory component."  Cornea. 2003 Mar;22(2):97-101.                  
37.    Spector SL, Surette ME.   "Diet and asthma: has the role of dietary lipids been overlooked in the management of asthma?" Ann Allergy Asthma Immunol. 2003 Apr;90(4):371-7            

    
38.    Belch JJ, Hill A.  "Evening primrose oil and borage oil in rheumatologic conditions." Am J Clin Nutr. 2000 Jan;71(1 Suppl):352S-6S.  

39.    Rothman D, DeLuca P, Zurier RB.  "Botanical lipids: effects on inflammation, immune responses, and rheumatoid arthritis." Semin Arthritis Rheum. 1995 Oct;25(2):87-96.         

        
40.    Furse RK, Rossetti RG, Seiler CM, Zurier RB.  "Oral administration of gammalinolenic acid, an unsaturated fatty acid with anti-inflammatory properties, modulates interleukin-1beta production by human monocytes."  J Clin Immunol. 2002 Mar;22(2):83-91.     

41.    http://www.umm.edu/altmed/articles/000305.htm#Possible%20Interactions

42.    Oh R.  "Practical applications of fish oil (Omega-3 fatty acids) in primary care."  J Am Board Fam Pract. 2005 Jan-Feb;18(1):28-36.           

 
43.    Reiffel JA, McDonald A.  "Antiarrhythmic effects of omega-3 fatty acids." Am J Cardiol. 2006 Aug 21;98(4A):50i-60i.            

 
44.    Robinson JG, Stone NJ.  "Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids." Am J Cardiol. 2006 Aug 21;98(4A):39i-49i.          

45.    Davidson MH.  "Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids." Am J Cardiol. 2006 Aug 21;98(4A):27i-33i. "    

46.    Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J.  "n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies:"    

47.    Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J.  "Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review."  Atherosclerosis. 2006 Nov;189(1):19-30.        

         
48.    Mickleborough TD.  "Dietary omega-3 polyunsaturated fatty acid supplementation and airway hyperresponsiveness in asthma." J Asthma. 2005 Jun;42(5):305-14.                

49.    Wild GE, Drozdowski L, Tartaglia C, Clandinin MT, Thomson AB. "Nutritional modulation of the inflammatory response in inflammatory bowel disease--from the molecular to the integrative to the clinical." World J Gastroenterol. 2007 Jan 7;13(1):1-7.     

50.    Peet M, Stokes C.  Omega-3 fatty acids in the treatment of psychiatric disorders.

51.    Drugs. 2005;65(8):1051-9.            

 
52.    Al-Hasani H, Joost HG.  "Nutrition-/diet-induced changes in gene expression in white adipose tissue." Best Pract Res Clin Endocrinol Metab. 2005 Dec;19(4):589-603.            

     
53.    Azain MJ.  Role of fatty acids in adipocyte growth and development.

54.    J Anim Sci. 2004 Mar;82(3):916-24.    

     
55.    James MJ, Proudman SM, Cleland LG.  "Dietary n-3 fats as adjunctive therapy in a prototypic inflammatory disease: issues and obstacles for use in rheumatoid arthritis."  Prostaglandins Leukot Essent Fatty Acids. 2003 Jun;68(6):399-405.             
56.    Simopoulos AP.  "Omega-3 fatty acids in inflammation and autoimmune diseases."  J Am Coll Nutr. 2002 Dec;21(6):495-505.

57.    Calder PC, Grimble RF. "Polyunsaturated fatty acids, inflammation and immunity."  Eur J Clin Nutr. 2002 Aug;56 Suppl 3:S14-9.

58.    Watkins BA, Li Y, Lippman HE, Seifert MF.  Omega-3 polyunsaturated fatty acids and skeletal health.

59.    Exp Biol Med (Maywood). 2001 Jun;226(6):485-97.  

60.    http://www.umm.edu/altmed/ConsSupplements/Interactions/Omega3FattyAcidscs.html

61.    Vashisht A, Wadsworth F, Carey A, Carey B, Studd J.  "A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen." Gynecol Endocrinol. 2005 Aug;21(2):101-5.     

62.    Holzer G, Riegler E, et al.  "Effects and side-effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study." Br J Dermatol. 2005 Sep;153(3):626-34.    

        
63.    Carey BJ, Carey AH, et al.  "A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women." BJOG. 2000 Jun;107(6):722-6.